about
Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker TeamThe Traumatic Brain Injury Endpoints Development (TED) Initiative: Progress on a Public-Private Regulatory Collaboration to Accelerate Diagnosis and Treatment of Traumatic Brain Injury.A multiple biomarker assay for quality assessment of botanical drugs using a versatile microfluidic chip.What evidence do we need for biomarker qualification?Current practices and future outlook on the integration of biomarkers in the drug development process.Industry Perspective on Biomarker Development and Qualification.
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 September 2015
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Industry perspectives on biomarker qualification.
@en
Industry perspectives on biomarker qualification.
@nl
type
label
Industry perspectives on biomarker qualification.
@en
Industry perspectives on biomarker qualification.
@nl
prefLabel
Industry perspectives on biomarker qualification.
@en
Industry perspectives on biomarker qualification.
@nl
P2860
P356
P1476
Industry perspectives on biomarker qualification.
@en
P2093
A W Womack
G Lavezzari
P2860
P304
P356
10.1002/CPT.264
P407
P577
2015-09-17T00:00:00Z
2016-02-01T00:00:00Z